Cargando…

Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study

OBJECTIVE: To evaluate the effectiveness, treatment patterns and long-term safety of ranibizumab 0.5 mg in treatment-naïve patients with central retinal vein occlusion (CRVO) in a real-world setting. METHODS: LUMINOUS, a 5-year, global, prospective, multicentre, multi-indication, observational, open...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lotery, Andrew, Clemens, Andreas, Tuli, Raman, Xu, Xun, Shimura, Masahiko, Nardi, Marco, Ziemssen, Focke, Dunger-Baldauf, Cornelia, Tadayoni, Ramin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307792/ https://www.ncbi.nlm.nih.gov/pubmed/34326500 http://dx.doi.org/10.1038/s41433-021-01702-y

Ejemplares similares

Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study
por: Pearce, Ian, et al.
Publicado: (2020)

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
por: Gerding, Heinrich, et al.
Publicado: (2015)

Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
por: Ziemssen, Focke, et al.
Publicado: (2017)

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
por: Callizo, Josep, et al.
Publicado: (2019)

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
por: Lotery, A J, et al.
Publicado: (2015)

Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020)

Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
por: Yasuda, Kanako, et al.
Publicado: (2023)

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022)

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
por: Hamilton, Robin D., et al.
Publicado: (2020)

Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters
por: Yasuda, Kanako, et al.
Publicado: (2023)

Cytokines and Pathogenesis of Central Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020)

Disease-modifying effects of ranibizumab for central retinal vein occlusion
por: Huang, Jason M., et al.
Publicado: (2021)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
por: Dogan, Emine, et al.
Publicado: (2018)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018)

Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2019)

Branch Retinal Vein Occlusion followed by Central Retinal Vein Occlusion
por: Moradian, Siamak, et al.
Publicado: (2009)

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study
por: Koh, Adrian, et al.
Publicado: (2020)

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study
por: Holz, Frank G., et al.
Publicado: (2020)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
por: Holz, Frank G., et al.
Publicado: (2020)

Relationship between retinal blood flow and cytokines in central retinal vein occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020)

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022)

Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
por: Aissopou, Evaggelia, et al.
Publicado: (2023)

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study
por: Pennington, Becky, et al.
Publicado: (2021)

Relationship between metamorphopsia and inner retinal microstructure following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Sugiura, Yoshimi, et al.
Publicado: (2021)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer, Michael A, et al.
Publicado: (2013)

Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2016)

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017)

Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Oshiro, Ayano, et al.
Publicado: (2021)

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
por: Ni, Weiyi, et al.
Publicado: (2021)

Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study
por: Mitchell, Paul, et al.
Publicado: (2020)

New individualized aflibercept treatment protocol for branch retinal vein occlusion with macular edema
por: Noma, Hidetaka, et al.
Publicado: (2023)

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
por: Hykin, Philip, et al.
Publicado: (2019)

Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy
por: McAllister, Ian L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1q5gel8kce4pnn2gbfm5d8c8ai